Mycenax Biotech Inc. (TPEX:4726)
Taiwan · Delayed Price · Currency is TWD 31.00
-0.65 (-2.05%)
At close: Mar 23, 2026
Mycenax Biotech Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -448.63 | -467.13 | -682.85 | -453.63 | -89.86 |
Depreciation & Amortization | 284.33 | 295.31 | 304.14 | 264.97 | 160.11 |
Other Amortization | - | 7.9 | 10.64 | 17.58 | 7.71 |
Loss (Gain) From Sale of Assets | -0.22 | - | - | 20.11 | -0.13 |
Asset Writedown & Restructuring Costs | 5.64 | - | - | - | - |
Loss (Gain) on Equity Investments | 21.13 | 12.94 | 8.7 | 0.76 | - |
Stock-Based Compensation | 20.13 | 6.96 | 7.7 | 9.81 | 11.18 |
Provision & Write-off of Bad Debts | -1.55 | 0.05 | -1.13 | 31.16 | -7.16 |
Other Operating Activities | -2.14 | 26.04 | 88.41 | -2.17 | -33.28 |
Change in Accounts Receivable | 11.41 | -82.26 | 23.92 | 17.79 | -144.69 |
Change in Inventory | -73.58 | 11.5 | 58.13 | -89.51 | -78.37 |
Change in Accounts Payable | 42.84 | -9.42 | -8.47 | -2.15 | 14.36 |
Change in Unearned Revenue | 130.84 | 43.57 | 45.01 | -9.84 | 26.21 |
Change in Other Net Operating Assets | -17.42 | -37.15 | 14.63 | 44.95 | -12.33 |
Operating Cash Flow | -27.24 | -191.68 | -131.18 | -150.19 | -146.23 |
Capital Expenditures | -88.54 | -330.43 | -295.63 | -626.94 | -1,098 |
Sale of Property, Plant & Equipment | 0.48 | - | - | - | 0.28 |
Sale (Purchase) of Intangibles | -10.54 | -0.08 | -1.97 | -12.04 | -14.98 |
Investment in Securities | -16.75 | 141.12 | -132.3 | -107.01 | 89.97 |
Other Investing Activities | 2.91 | 14.46 | -13.24 | 0.75 | -8.65 |
Investing Cash Flow | -112.44 | -174.93 | -443.15 | -745.24 | -1,031 |
Short-Term Debt Issued | 280 | - | - | 50 | - |
Long-Term Debt Issued | - | 123.12 | - | 272.2 | 490 |
Total Debt Issued | 280 | 123.12 | - | 322.2 | 490 |
Short-Term Debt Repaid | - | - | -100 | - | -50 |
Long-Term Debt Repaid | -190.52 | -42.51 | -146.32 | -36.99 | -29.61 |
Total Debt Repaid | -190.52 | -42.51 | -246.32 | -36.99 | -79.61 |
Net Debt Issued (Repaid) | 89.48 | 80.61 | -246.32 | 285.22 | 410.39 |
Issuance of Common Stock | 5.43 | 35.97 | 16.59 | 1,647 | 766.03 |
Other Financing Activities | - | - | - | - | -2.92 |
Financing Cash Flow | 94.91 | 116.58 | -229.73 | 1,932 | 1,174 |
Foreign Exchange Rate Adjustments | -0.24 | 0.33 | -0.04 | - | - |
Net Cash Flow | -45.02 | -249.7 | -804.1 | 1,036 | -4.21 |
Free Cash Flow | -115.78 | -522.11 | -426.81 | -777.12 | -1,244 |
Free Cash Flow Margin | -15.64% | -76.34% | -65.40% | -106.12% | -160.71% |
Free Cash Flow Per Share | -0.56 | -2.54 | -2.08 | -4.70 | -8.38 |
Cash Interest Paid | 30.35 | 26.56 | 23.07 | 23.04 | 27.47 |
Cash Income Tax Paid | -3.15 | 2.21 | 6.85 | 0.27 | 0.29 |
Levered Free Cash Flow | -31.77 | -489.76 | -6.76 | -662.5 | -1,168 |
Unlevered Free Cash Flow | -10.73 | -473.41 | 7.9 | -652.86 | -1,167 |
Change in Working Capital | 94.08 | -73.77 | 133.21 | -38.77 | -194.82 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.